Efficacy versus effectiveness trials: Informing guidelines for asthma management

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 1, 2013, Pages 50-57

  Price, David ^a   Hillyer, Elizabeth V ^b   Van Der Molen, Thys ^c  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Research in Real Life Ltd   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

asthma; effectiveness; efficacy; pragmatic; real life

Indexed keywords

BECLOMETASONE; BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHLOROFLUOROCARBON; CORTICOSTEROID; FLUTICASONE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; SHORT ACTING DRUG;

ANALYTIC METHOD; ASTHMA; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; DECISION MAKING; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ELECTRONIC MEDICAL RECORD; FOLLOW UP; GOLD STANDARD; HEALTH CARE PERSONNEL; HUMAN; INHALER; INTENTION TO TREAT ANALYSIS; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SMOKING; SYSTEMATIC ERROR;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ASTHMA; HUMANS; NEBULIZERS AND VAPORIZERS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84871998665     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32835ad059     Document Type: Review

References (68)

1. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. A national clinical guideline. May 2008, revised Jan 2012. http://www.sign.ac.uk/guidelines/fulltext/101/index. html. [Accessed 30 October 2012]
2. National Asthma Education and Prevention Program. Expert Panel Report 3: guidelines for the diagnosis and management of asthma. Full report 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf. [Accessed 30 October 2012]
3. Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention. http://www.ginasthma.org/. [Accessed 30 October 2012]
4. Krishnan JA, Schatz M, Apter AJ. A call for action: comparative effectiveness research in asthma. J Allergy Clin Immunol 2011; 127:123-127.
5. Price D, Chisholm A, van der Molen T, et al. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep 2011; 11:526-538.
6. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?'. Lancet 2005; 365:82-93.
7. Jarvinen TL, Sievanen H, Kannus P, et al. The true cost of pharmacological disease prevention. BMJ 2011; 342:d2175.
8. Dahlen SE, Dahlen B, Drazen JM. Asthma treatment guidelines meet the real world. N Engl J Med 2011; 364:1769-1770.
9. Holgate S, Bisgaard H, Bjermer L, et al. The Brussels Declaration: the need for change in asthma management. Eur Respir J 2008; 32:1433-1442.
10. Pinnock H, Ostrem A, Rodriguez MR, et al. Prioritising the respiratory research needs of primary care: the International Primary Care Respiratory Group (IPCRG) e-Delphi exercise. Prim Care Respir J 2012; 21:19-27.
11. Prasad V. The apples and oranges of cost-effectiveness. Cleve Clin J Med 2012; 79:377-379.
12. Rawlins MD. De Testimonio: on the evidence for decisions about the use of therapeutic interventions. Harveian Oration. London: Royal College of Physicians; 2008. http://bookshop.rcplondon.ac.uk/details.aspx?e=262. [Accessed 30 October 2012]
13. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290:1624-1632.
14. Chalkidou K, Tunis S, Whicher D, et al. The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness research. Clin Trials 2012; 9:436-446.
15. Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008; 337:a2390.
16. Ware JH, Hamel MB. Pragmatic trials-guides to better patient care? NEngl J Med 2011; 364:1685-1687.
17. Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. CMAJ 2009; 180:E47-E57.
18. Smith JR, Noble MJ, Musgrave S, et al. The at-risk registers in severe asthma (ARRISA) study: a cluster-randomised controlled trial examining effectiveness and costs in primary care. Thorax 2012. [Epub ahead of print]
19. Herland K, Akselsen JP, Skjonsberg OH, et al. How representative are clinical study patients with asthma or COPD for a larger 'real life' population of patients with obstructive lung disease? Respir Med 2005; 99:11-19.
20. Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008; 102:1681-1693.
21. Rand CS, Wright RJ, Cabana MD, et al. Mediators of asthma outcomes. J Allergy Clin Immunol 2012; 129:S136-S141.
22. Corrigan CJ. Asthma therapy: there are guidelines, and then there is real life. Prim Care Respir J 2011; 20:13-14.
23. Lotvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011; 127:355-360.
24. Price D, Bjermer L, Haughney J, et al. Real-life asthma strategies: the missing piece in the jigsaw. Treat Strategies (in press).
25. Konstantinou GN. Pragmatic trials: how to adjust for the 'Hawthorne effect'? Thorax 2012; 67:562.
26. Ryan D, Price D, Musgrave SD, et al. Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ 2012; 344:e1756.
27. Wechsler ME, Kelley JM, Boyd IO, et al. Active albuterol or placebo, sham acupuncture, or no intervention in asthma. N Engl J Med 2011; 365:119-126.
28. Staa TP, Goldacre B, Gulliford M, et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ 2012; 344:e55.
29. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342:1887-1892.
30. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009; 338:b81.
31. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4:e297.
32. Williams RJ, Tse T, Harlan WR, et al. Registration of observational studies: is it time? CMAJ 2010; 182:1638-1642.
33. Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011; 41:1521-1532.
34. Hyland ME, Whalley B, Halpin DM, et al. Frequency of nonasthma GP visits predicts asthma exacerbations: an observational study in general practice. Prim Care Respir J 2012. [Epub ahead of print]
35. Schatz M, Zeiger RS. Improving asthma outcomes in large populations. J Allergy Clin Immunol 2011; 128:273-277.
36. Blais L, Kettani FZ, Beauchesne MF, et al. New measure of adherence adjusted for prescription patterns: the case of adults with asthma treated with inhaled corticosteroid monotherapy. Ann Pharmacother 2011; 45:335-341.
37. Ivanova JI, Bergman R, Birnbaum HG, et al. Effect of asthma exacerbations on healthcare costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012; 129:1229-1235.
38. von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370:1453-1457.
39. Chauhan BF, Ducharme FM. Antileukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012; 5:CD002314.
40. Ducharme FM, Lasserson TJ, Cates CJ. Addition to inhaled corticosteroids of long-acting beta2-agonists versus antileukotrienes for chronic asthma. Cochrane Database Syst Rev 2011:CD003137.
41. Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364:1695-1707.
42. Ducharme FM, Noya FJ, Allen-Ramey FC, et al. Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin 2012;1:111-119.
43. Blais L, Kettani FZ, Lemiere C, et al. Inhaled corticosteroids vs. leukotriene-receptor antagonists and asthma exacerbations in children. Respir Med 2011; 105:846-855.
44. Shepherd J, Rogers G, Anderson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008; 12:iii-iv.
45. Lasserson TJ, Cates CJ, Lasserson EH, et al. Fluticasone versus 'extrafine' HFA-beclomethasone dipropionate for chronic asthma in adults and children [review]. Cochrane Database Syst Rev 2010:CD005309.
46. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma. Allergy Immunol Chest 2005; 127:335-371.
47. Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5:1-149.
48. Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol 2009; 124:S88-S93.
49. Price D, Martin RJ, Barnes N, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010; 126:511-518.
50. Brusselle G, Peche R, Van den Brande P, et al. Real-life effectiveness of extrafine beclometasone dipropionate/formoterol in adults with persistent asthma according to smoking status. Respir Med 2012; 106:811-819.
51. Muller V, Galffy G, Eszes N, et al. Asthma control in patients receiving inhaled corticosteroid and long-acting beta2-agonist fixed combinations: a real-life study comparing dry powder inhalers and a pressurized metered dose inhaler extrafine formulation. BMC Pulm Med 2011; 11:40.
52. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105:930-938.
53. Papi A, Haughney J, Virchow JC, et al. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J 2011; 37:982-985.
54. Price D, Haughney J, Sims E, et al. Effectiveness of inhaler types for real-world asthma management: retrospective observational study using the GPRD. J Asthma Allergy 2011; 4:37-47.
55. Price D, Roche N, Christian Virchow J, et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med 2011; 105:1457-1466.
56. Price D, Chrystyn H, Kaplan A, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res 2012; 4:184-191.
57. Kelly HW, Sternberg AL, Lescher R, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904-912.
58. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011; 364:2473-2475.
59. Kahn MG, Batson D, Schilling LM. Data model considerations for clinical effectiveness researchers. Med Care 2012; 50 (Suppl):S60-S67.
60. Desai JR, Wu P, Nichols GA, et al. Diabetes and asthma case identification, validation, and representativeness when using electronic health data to construct registries for comparative effectiveness and epidemiologic research. Med Care 2012; 50 (Suppl):S30-S35.
61. Methodology Committee of the Patient-Centered Outcomes Research Institute. Methodological standards and patient-centeredness in comparative effectiveness research: the PCORI perspective. JAMA 2012; 307:1636-1640.
62. Selby JV, Beal AC, Frank L. The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda. JAMA 2012; 307:1583-1584.
63. Gabriel SE, Normand SL. Getting the methods right: the foundation of patient-centered outcomes research. N Engl J Med 2012; 367:787-790.
64. Patient-Centered Outcomes Research Institute (PCORI). Draft methodology report. 23 July 2012. http://www.pcori.org/what-we-do/methodology/. [Accessed 30 October 2012]
65. Association of the British Pharmaceutical Industry (APBI). Demonstrating value with real world data. May 2011. http://www.abpi.org.uk/our-work/library/ guidelines/Pages/real-world-data.aspx. [Accessed 30 October 2012]
66. Busse WW, Morgan WJ, Taggart V, et al. Asthma outcomes workshop: overview. J Allergy Clin Immunol 2012; 129:S1-S8.
67. Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. J Allergy Clin Immunol 2012; 129:S24-S33.
68. Apter AJ. Advances in adult asthma diagnosis and treatment and health outcomes, education, delivery, and quality in 2011: what goes around comes around. J Allergy Clin Immunol 2012; 129:69-75.